Effect of Luseogliflozin on liver function, BNP and baPWV in diabetics with coronary artery disease

Abstract

Background: Luseogliflozin (SGLT2i) was originally developed as an anti-diabetic (DM) medicine. SGLT2i has several other effects such as anti-atherosclerotic, anti-NAFLD (non-alcoholic fatty liver disease), and decreases heart failure incidence through vascular function. This study aimed to investigate the effects of luseogliflozin on liver function, brain natriuretic peptide (BNP), and vascular function in DM patients with suspected NAFLD and coronary artery disease (CAD). Methods: Out of 201 patients prescribed SGLT2, 51 patients with poorly controlled diabetes (31 men, HbA1c > 6.5%; 78 ±8 years old) as well as suspected NAFLD and CAD treated with luseogliflozin at 2.5 mg daily for 12 months and measured following clinical tests were selected. Blood serum indices of liver function (serum aspartate aminotransferase [AST], serum alanine aminotransferase [ALT], γ-glutamyl transpeptidase [γ-GTP]), brain natriuretic peptide (BNP), fasting blood sugar (FBS), and HbA1c were measured before and every 6 months until 12 months after commencing luseogliflozin treatment. BaPVW was recorded before treatment and 12 months after starting treatment. Results: Luseogliflozin decreased body weight (BW) from 64±10 kg by 8% after 12 months of treatment, whereas no changes in heart rate and blood pressure were observed. In addition, luseogliflozin improved AST, ALT, and γ-GTP as well as FBS and HbA1c. At 6 months, luseogliflozin significantly decreased BW by 6%, and improved γ-GTP (36±35 vs. 28±19 U/L, P < 0.05), HbA1 (7.3±0.8 vs. 6.8±0.8%, P < 0.05), BNP (108±60 vs. 65±37 pg/mL, P < 0.05), and baPWV (1,810±311 vs. 1,662±233 cm/s, P < 0.05). Conclusion: Results suggest that luseogliflozin has salutary effects on anti-NAFLD, BNP, and baPWV even if some fluctuating diabetic controls exit. This might indicate possible anecdotal ameliorating effects of prognosis in diabetics with CAD by luseogliflozin.